Complement Inhibition in Immunoglobulin A Nephropathy: A Mini-Review
- 20 December 2025
- journal article
- review article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 87 (3) , 412-421
Abstract
No abstract availableKeywords
Funding Information
- Bayer
- Novartis
- California State Library
- Irish Nephrology Society
This publication has 45 references indexed in Scilit:
- Carboxymethyl-lysine is a Prominent Target of Circulating IgA in IgA NephropathyKidney International Reports, 2025
- Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular DiseasesKidney International Reports, 2023
- Eculizumab as a therapeutic approach for severe crescentic recurrence of immunoglobulin A nephropathy after kidney transplantationAmerican Journal of Transplantation, 2023
- Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsyKidney International, 2022
- Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA NephropathyKidney International Reports, 2020
- Predictive value of mesangial C3 and C4d deposition in IgA nephropathyClinical Immunology, 2020
- Evaluating a New International Risk-Prediction Tool in IgA NephropathyJAMA Internal Medicine, 2019
- Progressive IgA Nephropathy Is Associated With Low Circulating Mannan-Binding Lectin–Associated Serine Protease-3 (MASP-3) and Increased Glomerular Factor H–Related Protein-5 (FHR5) DepositionKidney International Reports, 2018
- Circulating complement factor H–related proteins 1 and 5 correlate with disease activity in IgA nephropathyKidney International, 2017
- Complement 3 is involved in changing the phenotype of human glomerular mesangial cellsJournal of Cellular Physiology, 2007